You just read:

Guerbet concurs with the PRAC Recommendations on Gadolinium-based Contrast Agents and announces changes to the US labeling for its linear agent Optimark® (gadoversetamide injection)

News provided by

Guerbet LLC

Mar 31, 2017, 10:17 ET